Abstracts tagged "Adalimumab"

Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: 503 • 2019 ACR/ARP Annual Meeting
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Edward Keystone¹, Daniel Furst ², Malcolm Boyce ³, Frans van den Berg ³, SangJoon Lee ⁴, SungHyun Kim ⁴, YunJu Bae ⁴, GoEun Yang ⁴, JuHeon Koo ⁴, EunJin Choi ⁴ and Jonathan Kay ⁵, ¹Mount Sinai Hospital, Toronto, Canada, ²University of California, Los Angeles, CA, ³Hammersmith Medicines Research, London, United Kingdom, ⁴Celltrion Inc., Incheon, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
Abstract Number: 1407 • 2019 ACR/ARP Annual Meeting
Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis
Peter Taylor¹, Janet Pope ², Kei Ikeda ³, Xiang Zhang ⁴, Bochao Jia ⁴, Hong Zhang ⁵, Amanda Quebe ⁴, Yun-Fei Chen ⁴, Carol Gaich ⁴, Thorsten Holzkaemper ⁴, Anabela Cardoso ⁴ and Anthony Sebba ⁶, ¹University of Oxford, Oxford, United Kingdom, ²Western University, London, ON, Canada, ³Chiba University Hospital, Chiba, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵TechData Services, King of Prussia, PA, ⁶University of South Florida, Palm Harbor, FL
Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA…
Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Jane Buckner¹, Vivian Bykerk ², V. Michael Holers ³, S. Louis Bridges ⁴, William Rigby ⁵, Sheng Gao ⁶, Marleen Nys ⁷ and Neelanjana Ray ⁸, ¹Benaroya Research Institute, Seattle, WA, ²Hospital for Special Surgery, New York City, NY, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁴University of Alabama at Birmingham, Birmingham, ⁵Dartmouth-Hitchcock Medical Center, Lebanon, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁸Bristol-Myers Squibb, Princeton
Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Janet Pope¹, Yvonne Lee ², Jeffrey Curtis ³, Daojun Mo ⁴, Terence Rooney ⁴, Li Xie ⁴, Christina Dickson ⁴, Douglas Schlichting ⁴, Amanda Quebe ⁴, Anabela Cardoso ⁴, Lee Simon ⁵ and Peter Taylor ⁶, ¹Western University, London, ON, Canada, ²Northwestern University Feinberg School of Medicine, Chicago, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵SDG LLC, Cambridge, MA, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting
Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
Najima Mwase ¹, Theresa Hennard ², Joseph McDonald ³, Amy Cassedy ⁴, Onengiya Harry ³ and Sheila Angeles-Han⁵, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Roy Fleischmann¹, Mark Genovese ², Ricardo Blanco ³, Stephen Hall ⁴, Glen Thomson ⁵, Filip Van den Bosch ⁶, Cristiano A. Zerbini ⁷, Jose Jeffrey Enejosa ⁸, Yihan Li ⁹, Ryan DeMasi ⁹ and In-Ho Song ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University, Stanford, CA, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Monash University and Emeritus Research, Melbourne, Australia, ⁵CIADS Research, Winnipeg, Canada, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁹AbbVie Inc., North Chicago, IL
Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…
Abstract Number: 1986 • 2018 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization
Bohdan P. Harvey, Joel Cohen-Solal and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis (OCgenesis) independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast…
Abstract Number: 2593 • 2018 ACR/ARHP Annual Meeting
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
Xu Huji¹, Li Zhijun², Wu Jian³, Xing Qian⁴, Guixiu Shi⁵, Li Juan⁶, Liu Xu⁷, Lijun Wu⁸, Li Xiaomei⁹, Tan Wenfeng¹⁰, Dongyi He¹¹, Bi Liqi¹², Li Hongbin¹³, Xiao Zhengyu¹⁴, Shuai Zongwen¹⁵, Li Xiaoxia¹⁶, Wang Yongfu¹⁷, Luo Li¹⁸, Zheng Yi¹⁹, Xiao Weiguo²⁰, Zhou Hui²¹, Lu Yushan²¹, Zheng Shirui²¹ and Wang Xiong²¹, ¹Shanghai Changzheng Hospital, Shanghai, China, ²The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ³The First Affiliated Hospital of Soochow University, Suzhou, China, ⁴Qingdao municipal hospital, Qingdao, China, ⁵The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁷Peking University People’s Hospitalv, Beijing, China, ⁸People's Hospital of Xinjiang Uygur Autonomous Region, Wulumuqi, China, ⁹Anhui Provincial Hospital, Hefei, China, ¹⁰Jiangsu Province Hospital, Nanjing, China, ¹¹Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China, ¹²China-Japan Friendship Hospital, Changchun, China, ¹³The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China, ¹⁴The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ¹⁵The First Affiliated Hospital of Anhui Medical University, Hefei, China, ¹⁶Xuanwu Hospital Capital Medical University, Beijing, China, ¹⁷The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science & Technology, Baotou, China, ¹⁸The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China, ¹⁹Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China, ²⁰The First Hospital of China Medical University, Shenyang, China, ²¹Innovent Biologics (Suzhou) Co. Ltd, Shanghai, China
Background/Purpose: IBI303, an injection of recombinant human anti-tumor necrosis factor-α monoclonal antibody, is adalimumab biosimilar candidate. Physicochemical properties assessment and non-clinical studies showed the structure,…
Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
Abstract Number: 2173 • 2018 ACR/ARHP Annual Meeting
Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naïve Patients in the United Kingdom
Kateryna Onishchenko¹, Miriam Tarallo², Cinzia Curiale² and Stamatia Theodora Alexopoulos¹, ¹Consulting at McCann Health, London, United Kingdom, ²Pfizer, Rome, Italy
Background/Purpose: Etanercept and adalimumab are TNFα inhibitors, both indicated in the UK for the treatment of patients with moderate-to-severe active RA who had inadequate response…
Abstract Number: 2606 • 2018 ACR/ARHP Annual Meeting
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
Laura C. Coates¹, Philip J. Mease², Kun Chen³, Maja Hojnik⁴, Wendell Valdecantos³, Pranav Sheth⁵, Daniel Aletaha⁶ and Fabiana Ganz⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Swedish Medical Centre and University of Washington, Seattle, WA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵Group Health Associates, Trihealth, Cincinnati, OH, ⁶Medical University of Vienna, Vienna, Austria, ⁷AbbVie AG, Baar, Switzerland
Background/Purpose: Adalimumab (ADA) inhibited radiographic progression in patients (pts) with moderate to severe PsA in the ADEPT study and its open label extension (OLE). These…
Abstract Number: 562 • 2018 ACR/ARHP Annual Meeting
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
Paul Emery¹, Gerd R. Burmester², Esperanza Naredo³, Ivan Lagunes Galindo⁴, Ying Zhang⁵, Xin Wang⁵, Maja Hojnik⁶ and Philip G. Conaghan⁷, ¹University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL, ⁶AbbVie, Ljubljana, Slovenia, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: ACR and EULAR recommend bDMARD tapering in patients (pts) with rheumatoid arthritis (RA) who achieved stable clinical remission. Yet, there are limited systematically collected…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.